A direct UK trial comparison puts the headline result beyond doubt: at 72 weeks, Mounjaro produced 20.2% average weight loss, compared with 13.7% for Wegovy 2.4 mg among adults with obesity. The same trial found that 32% of people taking Mounjaro lost at least 25% of their starting body weight, versus 16% taking Wegovy, while average waist reduction was 18 cm versus 13 cm (British Heart Foundation summary of the trial).

That makes Mounjaro the average winner in the standard-dose head-to-head evidence. But a simple “Mounjaro wins” conclusion misses the questions that determine real treatment choice in the UK: which dose is being compared, whether a person meets NHS criteria, how well they tolerate escalation, and whether the treatment can be continued under proper clinical supervision.

The comparison also changed with the reported approval of Wegovy 7.2 mg in January 2026. Trial data associated with that higher dose showed 20.7% average weight loss, close to the 20.2% reported for Mounjaro in SURMOUNT-5 (Second Nature's UK-focused overview). The clinically useful question is therefore not only which brand is stronger, but which medicine, dose and access pathway offer the most suitable balance of effect, tolerability and sustainability.

Table of Contents

• What Mounjaro and Wegovy Are in the UK
• How Each Medicine Works in the Body
• Comparing Weight Loss Results From Trials
• Dosing, Injections and Day-to-Day Use
  • Why escalation is part of treatment
  • The first months in practice
• Side Effects and Safety Considerations
  • What patients should monitor
  • Situations requiring particular caution
• UK Eligibility and Access Pathways
  • Why the pathway changes the comparison
• Which Option Fits Which Patient
  • Patient factors that can change the decision
• Common Questions About Mounjaro and Wegovy in the UK

What Mounjaro and Wegovy Are in the UK

An adult considering weight-management injections may see Mounjaro and Wegovy presented as interchangeable options. They aren't identical products, although both are prescription medicines used for chronic weight management and both belong to the incretin-based treatment group used alongside dietary and activity changes.

Mounjaro contains tirzepatide, while Wegovy contains semaglutide. Mounjaro acts on two hormone pathways, GIP and GLP-1. Wegovy acts on the GLP-1 receptor. That pharmacological distinction matters because the medicines can produce different average responses, even though both aim to reduce appetite and support weight loss.

Both are UK-licensed GLP-1 medicines for weight management, and UK government information identifies Wegovy and Mounjaro among the only GLP-1 receptor agonist products licensed for weight management in the UK (NHS England guidance on weight-management injections). Their weight-management use should be distinguished from formulations or doses prescribed for type 2 diabetes. A prescription for one purpose doesn't automatically establish suitability for another.

The practical context is equally important. These medicines aren't standalone fixes. NICE recommends tirzepatide alongside a reduced-calorie diet and increased physical activity, and its appraisal is based on evidence from the SURMOUNT programme (NICE guidance on tirzepatide). A prescriber must also consider medical history, current medicines, contraindications, treatment goals and the ability to attend follow-up.

For readers exploring how incretin medicines differ from other emerging concepts, an explanation of GLP-3 and related weight-loss terminology can help separate established treatments from speculative language. The rest of the comparison should therefore be treated as a clinical decision, not a product popularity contest.

How Each Medicine Works in the Body

Wegovy is a GLP-1 receptor agonist. It imitates the action of glucagon-like peptide-1, a hormone involved in appetite regulation, digestion and blood-glucose control. In practical terms, GLP-1 activity can help a person feel fuller, reduce appetite and slow the movement of food through the stomach.

That mechanism affects eating behaviour rather than “burning fat”. A person may find that smaller portions feel sufficient, hunger arrives less often, or highly tempting food becomes easier to resist. The response isn't uniform, and the medicine can't remove the need for an eating pattern that provides adequate nutrition.

Mounjaro, or tirzepatide, activates both GIP and GLP-1 receptors. GIP, glucose-dependent insulinotropic polypeptide, is another incretin hormone. The dual action is biologically relevant because it engages two related pathways involved in appetite, insulin response and energy regulation rather than relying on GLP-1 activity alone.

Clinical interpretation: A dual mechanism explains why tirzepatide may have a larger average effect, but it doesn't identify the individual who will tolerate it best or achieve the greatest result.

The trial evidence supports a difference in average weight reduction, but mechanism and outcome aren't the same thing. In SURMOUNT-5, the dual-acting medicine outperformed semaglutide 2.4 mg at the reported endpoint, yet individual weight change still varied. Some people may stop escalation because gastrointestinal effects become difficult, while others may respond adequately at a lower tolerated dose.

Blood-sugar effects also need context. Both medicines influence glucose-related physiology, but a person's diabetes status, prescribed medicines and risk of low blood sugar can alter clinical management. Someone using insulin or a sulfonylurea may need particular review, because combining glucose-lowering treatments can change hypoglycaemia risk.

The useful conclusion is narrow but important. Mounjaro's dual receptor activity provides a plausible biological basis for its stronger average trial result, while Wegovy remains an effective GLP-1 treatment with substantial evidence of weight reduction. Neither mechanism predicts an automatic personal winner.

Comparing Weight Loss Results From Trials

The direct comparison favours tirzepatide at the standard doses studied. In SURMOUNT-5, 751 participants were randomised. By week 72, the least-squares mean change in body weight was -20.2% with tirzepatide versus -13.7% with semaglutide 2.4 mg, with P<0.001 (PubMed record for SURMOUNT-5).

The difference extends beyond average scale weight. Tirzepatide produced a greater mean reduction in waist circumference, and more participants reached at least 25% weight loss, according to the British Heart Foundation's trial summary. These findings describe group averages, not an expected result for every patient. Tolerability, dose escalation and treatment continuation can all affect individual outcomes.

Earlier placebo-controlled evidence supports semaglutide's effectiveness. In STEP 1, semaglutide 2.4 mg produced 14.9% mean weight loss after 68 weeks. A review covering STEP 1 to STEP 5 reported a semaglutide weight-loss range of 9.6% to 16.0% versus placebo (MedPage Today summary of semaglutide trial evidence). Direct comparisons between separate trials remain limited because participant characteristics, comparators, follow-up periods and study conditions differ.

Dose changes the interpretation. UK-facing reporting says MHRA approved Wegovy 7.2 mg in January 2026, with 20.7% average weight loss in trial data. The same report says one-third of participants receiving 7.2 mg achieved at least 25% weight loss. That result is close to the standard-dose tirzepatide outcome, although it should not be treated as a replacement for a direct head-to-head comparison. The higher Wegovy dose also requires clinical selection and supervision, as discussed in Second Nature's review of the higher Wegovy dose.

Trim's comparison of Mounjaro and Wegovy trial data explains how head-to-head findings relate to clinical guidance. For nutrition planning, an assessment can help patients discover your calorie needs, although this does not determine prescription suitability.

The evidence supports a dose-aware conclusion: Mounjaro produced the stronger standard-dose head-to-head result, while higher-dose Wegovy narrows that numerical gap. A six-month review of weight change, tolerability and access eligibility can help clinicians decide whether the current treatment remains appropriate.

Dosing, Injections and Day-to-Day Use

Both medicines are administered as once-weekly subcutaneous injections, so the basic rhythm is similar. The practical differences appear during dose escalation, device handling and the point at which a prescriber decides that a person has reached a suitable maintenance dose.

Wegovy generally progresses through 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, with escalation spread across 16 weeks. The higher 7.2 mg option is a newer development and should only be considered for selected patients under medical supervision. Mounjaro follows a different sequence, moving through 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg over roughly 20 weeks.

Why escalation is part of treatment

The starting dose isn't intended to deliver the full weight-loss effect. It allows the body to adjust gradually, particularly to gastrointestinal effects. Increasing too quickly can make nausea, vomiting, diarrhoea or constipation more difficult to manage, so a prescriber may delay an increase or retain a person at the highest dose they tolerate.

The weekly schedule also creates routine. Patients need to choose an injection day, understand what to do after a missed dose, store the pen correctly and avoid changing the dose without clinical advice. Although both products use pre-filled pen devices, exact preparation, storage instructions and missed-dose rules should be checked against the current product information supplied with the prescription.

The first months in practice

During the early months, the main decision isn't solely whether the scales are moving. A clinician should consider appetite response, adverse effects, hydration, nutrition, other medicines and whether the next dose step remains appropriate. The “maximum” dose isn't automatically the right dose if a lower dose provides a useful response with better tolerability.

This is why dosing comparisons can't be reduced to the largest number on a pen. A sustainable tolerated dose is more clinically relevant than an ambitious dose that leads to interruption or discontinuation.

Side Effects and Safety Considerations

Mounjaro and Wegovy share a broadly similar pattern of common adverse effects because both influence appetite, digestion and gastrointestinal motility. Patients commonly report nausea, vomiting, diarrhoea and constipation, particularly while the dose is increasing. The intensity and duration vary, and symptoms that are manageable for one person may be unacceptable for another.

What patients should monitor

A safe programme needs more than a symptom list. Patients should tell their prescriber about persistent vomiting, severe abdominal pain, symptoms suggesting dehydration, marked constipation or an inability to eat and drink adequately. Possible complications requiring medical assessment include pancreatitis, gallbladder disease and delayed stomach emptying, sometimes described as gastroparesis.

People with diabetes need an additional layer of review. The risk of hypoglycaemia can increase when these medicines are combined with insulin or sulfonylureas, so glucose-lowering treatment may need adjustment by the relevant clinician.

• Before starting: disclose previous pancreatitis, gallbladder problems, significant digestive symptoms and every prescribed medicine.
• During escalation: report symptoms before increasing the dose rather than treating the schedule as fixed.
• During maintenance: seek advice if side effects return, weight loss becomes excessive or eating and drinking become difficult.

Situations requiring particular caution

Neither medicine should be treated as suitable for everyone. Pregnancy requires specific clinical advice, and people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should discuss this with a prescriber before treatment. Pregnancy planning and breastfeeding also require an individual review rather than assumptions based on someone else's experience.

NICE's tirzepatide appraisal describes treatment as part of a reduced-calorie diet and increased physical activity programme, not an isolated injection (NICE tirzepatide technology appraisal). A UK-registered prescriber should review medical history, contraindications and concurrent medicines before issuing either product.

UK Eligibility and Access Pathways

The strongest trial result doesn't automatically determine which medicine a UK patient can receive. NICE recommendations and NHS commissioning pathways shape access, and the criteria differ between medicines and settings.

NHS England states that Wegovy may be prescribed for people meeting BMI thresholds starting at 35, or 32.5 for some ethnic groups, within the relevant weight-management pathway (NHS England patient guidance). Those thresholds are access rules, not a prediction of how much weight a person will lose.

For Mounjaro, NICE recommends treatment for adults with BMI of at least 35 kg/m² plus at least one weight-related comorbidity, within specialist NHS weight-management services. NICE also says treatment should be reviewed after 6 months on the highest tolerated dose. If the person has lost less than 5% of initial body weight, continuation should be reconsidered (NICE recommendation for tirzepatide).

Why the pathway changes the comparison

The 6-month rule creates a practical benchmark. It doesn't mean every person who falls short has failed, nor does it replace clinical judgement. It does mean that NHS treatment involves a defined review point where response, tolerability and ongoing benefit must be assessed.

NHS access may also depend on specialist service capacity and local implementation. A patient could therefore find that the theoretically preferred medicine isn't immediately available through their local pathway. Private prescribing follows a different process, but it still requires a legitimate clinical assessment, appropriate prescription and regulated dispensing.

Readers comparing routes can review practical information about how to get Wegovy in the UK, while remembering that eligibility isn't established by an online questionnaire alone. A GPhC-registered pharmacy may dispense prescribed treatment, but a prescriber remains responsible for deciding whether it is clinically appropriate.

Which Option Fits Which Patient

The average trial result favours Mounjaro, but prescribing decisions shouldn't begin and end with that figure. The relevant question is whether the person can access, tolerate and continue the dose that produced the evidence.

For someone prioritising average weight reduction: Mounjaro has the stronger standard-dose head-to-head result, particularly at the higher tirzepatide doses assessed in SURMOUNT-5.

NICE's evidence review concluded that tirzepatide 10 mg and 15 mg were statistically superior to semaglutide for the trial's minimum 5% weight-loss endpoint, and that tirzepatide 15 mg was statistically significantly more effective for weight loss in the target population (NICE committee evidence review). That supports considering Mounjaro when a patient has a suitable clinical profile and can manage escalation.

Wegovy may still be the more sensible option when access, familiarity or tolerability carries greater weight. A clinician may favour it for a person who responds well to GLP-1 treatment, prefers its established dosing pathway or doesn't need to pursue the maximum available dose. The new 7.2 mg option also means the comparison can no longer assume that semaglutide stops at 2.4 mg, although suitability for that dose must be assessed medically.

Patient factors that can change the decision

• Medical history: Diabetes treatment, digestive conditions, gallbladder history and pregnancy plans can outweigh average efficacy.
• Tolerability: A lower tolerated dose may offer more value than a higher dose that causes persistent gastrointestinal symptoms.
• Access: NHS criteria, specialist service availability and private prescribing arrangements can determine which option is realistic.
• Treatment priorities: A person focused on appetite control, waist reduction, glucose management or long-term maintenance may need a different discussion from someone focused solely on scale weight.

Trim is one UK option that combines prescribing assessment with ongoing support, nutrition and activity guidance, and progress monitoring. Whatever provider a person chooses, treatment should be supplied through an appropriate regulated pathway and reviewed by a UK-registered clinician.

The best interpretation of the evidence is conditional rather than absolute. Mounjaro leads in the standard-dose trial comparison, while Wegovy can remain reasonable when its access, tolerability or dose pathway better matches the patient.

Common Questions About Mounjaro and Wegovy in the UK

Can someone switch between Wegovy and Mounjaro?
A switch may be possible, but it shouldn't be made independently. The prescriber needs to review the current dose, last injection, side effects, medical history and an appropriate starting plan for the new medicine.

How long are they used for?
Both are intended for chronic weight management. Duration depends on response, adverse effects, health goals, continued eligibility and whether the benefits justify ongoing treatment. Stopping can change appetite and weight-management needs, so a planned review is safer than an abrupt self-directed decision.

What happens if the 5% benchmark isn't reached?
For Mounjaro in the relevant NHS pathway, NICE says continuation should be reconsidered when a person has lost less than 5% of initial body weight after 6 months on the highest tolerated dose (NICE continuation recommendation). Reconsideration may involve checking adherence, dose tolerance, other medicines, health conditions and alternative strategies.

Can either medicine be used during pregnancy, pregnancy planning or breastfeeding?
Don't start, continue or stop treatment in these circumstances without medical advice. A prescriber should discuss pregnancy intentions, contraception where relevant and breastfeeding before treatment begins.

What should supervision include?
A proper programme should include eligibility screening, medicine review, dose-escalation support, side-effect monitoring, nutrition advice, physical-activity planning and scheduled reassessment. The injection is only one component of weight management.

Trim offers medically supervised access to Mounjaro and Wegovy through UK-registered clinicians, with ongoing support and progress guidance rather than a prescription in isolation. If you're comparing the two options, visit Trim to complete an assessment and discuss which treatment pathway may be clinically suitable for you.